Antiallergic marine biopolymers

An allergy and composition technology, applied in the fields of physiology and immunology, can solve the problems of large side effects and little effect of treatment of chronic allergic disorders

Active Publication Date: 2011-05-18
MARINOMED BIOTECHNOLOGIE GMBH
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs, while helpful in reducing the symptoms of acute allergic reactions, are less effective in the treatment of chronic allergic disorders
All of the above drugs contain considerable side effects, especially after long-term use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antiallergic marine biopolymers
  • Antiallergic marine biopolymers
  • Antiallergic marine biopolymers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1: Inhibition of TNF-α production by IgE / antigen-stimulated mast cells.

[0024] TNF-[alpha] is a central mediator of the inflammatory response observed in infectious and autoimmune diseases and is released by leukocytes, mast cells, endothelial cells, and several other tissues during injury. Cell-based assays using mouse mast cells stimulated with IgE / antigen complexes showed that both iota-carrageenan and kappa-carrageenan inhibited TNF-α release, whereas lambda-carrageenan did not ( figure 1 ).

[0025] CFTL12 mast cells were incubated with iota-carrageenan or kappa-carrageenan at a concentration of 200 μg / ml. After 60 minutes the cells were stimulated with IgE / antigen complexes. Cells were incubated at 37°C for 6 hours, and TNF-α in the supernatant was determined by a commercial mouse TNF-α ELISA (Bender-Med-Systems). Error bars represent standard deviation among 4 independent wells.

[0026] 1 = no stimulation; 2 = IgE / antigen stimulation; 3 = λ-carrag...

Embodiment 2

[0027] Example 2: Dose-dependent inhibition of TNF-α production by IgE / antigen-stimulated mast cells

[0028] Mast cells were incubated with various concentrations of iota-carrageenan. After 60 minutes the cells were stimulated with IgE / antigen complexes. Cells were incubated at 37°C for 6 hours, and TNF-α in the supernatant was determined using a commercially available mouse TNF-α ELISA (Bender-Med-Systems). The result is as figure 2 shown. Error bars represent standard deviation among 4 independent wells. 1 = unstimulated; 2 = stimulated with IgE / antigen; 3 = iota-carrageenan at 200 μg / ml; 4 = iota-carrageenan at 66 μg / ml; 5 = iota-carrageenan at 6.6 μg / ml Vegetarian gum; 6 = iota-carrageenan at 0.6 μg / ml. The Y-axis represents the concentration of TNF-α in pg / ml.

Embodiment 3

[0029] Example 3: Application of Carrageenan Nasal Spray in Improving Allergy Symptoms

[0030] A 29-year-old patient with a well-documented history of type I anaphylaxis, intense symptoms of allergic rhinitis and hypersensitivity to several plant pollens led him to the following regimen: nightly administration of iota-carrageenan nasal spray, and increase the dose during pollen season. The patient reported that the frequency of sneezing had decreased significantly during the use of the nasal spray and that he could sleep undisturbed again. In addition, the patient reported a decrease in inflammation of the nasal mucosa. The patient further reported no need for additional medications, particularly intranasal decongestants, antihistamines, and corticosteroids, in stark contrast to previous pollen seasons.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to pharmaceutical compositions based on carrageenan as an active ingredient, for use as a medicament in the prophylactic or therapeutic treatment of allergic conditions or diseases, with the proviso that the carrageenan comprises iota- and/or kappa-carrageenan and is substantially free of lambda carrageenan. Typically, the invention relates to liquid formulations, gels and dry powder compositions comprising iota- and/or kappa-carrageenan and, optionally, one or more non-carrageenan therapeutic agents for administration to the respiratory tract, the gastrointestinal tract or the eyes. The compositions of the invention have been found to be efficacious in the prevention and treatment of type I allergies and additionally, may exert an adjuvant function upon combined mucosal administration with non-carrageenan therapeutic agents.

Description

technical field [0001] The invention belongs to the field of physiology and immunology, and relates to the application of carrageenan in the preventive or therapeutic treatment of allergic reactions. Background technique [0002] Structurally, carrageenans are a complex group of polysaccharides composed of repeating galactose-related monomer units. Currently, carrageenan can be distinguished into three main types, namely lambda-carrageenan, kappa-carrageenan and iota-carrageenan. The lambda form does not gel strongly at room temperature and thus allows administration by injection, eg to induce an inflammatory response. Inflammation induced by carrageenan has been well studied and highly reproducible. The main signs of inflammation, namely edema, hyperalgesia and erythema, appear immediately after subcutaneous injection of λ-carrageenan and are usually caused by the action of pro-inflammatory factors present in situ at the site of injury or next to infiltrating cells, The ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/731A61P11/06A61P27/14A61P37/08
CPCA61K31/731A61P11/00A61P11/06A61P11/12A61P19/02A61P27/00A61P27/02A61P27/14A61P37/00A61P37/08A61K2300/00
Inventor 安德里亚·格拉索尔伊娃·普里斯赫-格拉索尔
Owner MARINOMED BIOTECHNOLOGIE GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap